YD Bio (YDES) Stock Price, News & Analysis

Company Overview

YD Bio Limited is a biotechnology company focused on the development of DNA methylation-based cancer detection technologies and ophthalmologic innovations. The company also provides clinical trial support and related research services.

YD Bio Limited is headquartered in Taipei, Taiwan, and its ordinary shares trade on the Nasdaq Global Market under the ticker symbol YDES.

Key Stats

• Today's Range: $3.61 to $4.19
• 50-Day Range: $1.96 to $4.80
• 52-Week Range: $1.70 to $25.00
• Volume: 819,273 shs
• Average Volume: 307,473 shs
• Market Capitalization: $283.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

YD Bio Stock Analysis - MarketRank™

YD Bio scored higher than 34% of companies evaluated by MarketBeat, and ranked 747th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

YD Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

YD Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of YD Bio has been sold short.

Short Interest Ratio / Days to Cover

YD Bio has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in YD Bio has recently decreased by 22.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

YD Bio does not currently pay a dividend.

Dividend Growth

YD Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.19

News Sentiment

YD Bio has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for YD Bio this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $12,183.00 in company stock, which represents 0.0043% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, YD Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,183.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

YD Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/01/2026
• Today: 9/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:YDES
• CIK: 2011674
• Web: N/A
• Phone: N/A
• Fax: N/A
• Employees: N/A
• Year Founded: 2025

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 70,790,000
• Free Float: N/A
• Market Cap: $283.16 million
• Optionable: N/A
• Beta: N/A